Nothing has changed with IPIX to support the recent pullback. Kevetrin is still hovering in the background. OM and IBD uses are almost certainly under negotiation at this time. Current testing for use as an adjunct treatment for the Corona virus problem is underway as we speak and can only be viewed as an unexpected bonus for the company. It is not realistic to expect overnight results on this current part of the IPIX story or to turn negative because Trump didn't specifically mention Brilacidin or IPIX today. And the other potentials, now apparently in the background for too many, seem to have been conveniently forgotten. Who could realistically be negative on this current situation and for what logical reasons?